Blog - INTERNET MÉDICA

Complicações Neurológicas da COVID-19 (Neurological Complications of Covid-19 Infection)

Por Paulo Leite 23/01/2021

– As manifestações neurológicas causadas pela COVID-19 ainda não estão completamente elucidadas.

– O comprometimento neurológico pode decorrer de um efeito viral direto em neurônios ou em células gliais, a efeito imunomediado em resposta à infecção viral, ou de um efeito secundário a estados de hipercoagulabilidade e danos endoteliais, assim como decorrente de complicações sistêmicas graves relacionadas a cuidados intensivos prolongados na unidade de terapia intensiva.

■ Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

J Matschke, M Lütgehetmann,P C Hagel et al

The Lancet Neurology 2020, ,vol 19 (11)

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30308-2/fulltext

■ Neurological associations of COVID-19

M A Ellul, L Benjamin, B Singh et al

The Lancet Neurology 2020, ,vol 19 (9)

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30221-0/fulltext

■ The neurology of COVID-19 revised: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries

Gustavo C. Román, Peter S. Spencer, Jacques Reis et al

on behalf of the WFN Environmental Neurology Specialty Group

J Neurol Sci. 2020 Jul 15; 414: 116884

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204734/

■ Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases

Samir Abu-Rumeileh, Ahmed Abdelhak, Matteo Foschi et al

J Neurol. 2020 Aug 25 : 1–38

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445716/

■ Neuropsychiatric changes during the COVID-19 pandemic in multiple sclerosis patients

Demir, Caner Feyzi, BILEK, Furkan and Balgetir, Ferhat

Arq. Neuro-Psiquiatr., Sept 2020, vol.78, no.9, p.570-575

https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000900570&lng=pt&nrm=iso&tlng=en

■ Late onset of Guillain-Barré syndrome following SARS-CoV-2: part of ¨long COVID-19 syndrome?

M M Raahimi, A Kane, C EG Moore, A W Alareed

BMJ Case Reports 2021, vol 14 (1)

https://casereports.bmj.com/content/14/1/e240178

■ Guillain-Barré syndrome and COVID-19: association or coincidence

A Gale, S Sabaretnam, A Lewinsohn

BMJ Case Reports 2020, vol 13 (11)

https://casereports.bmj.com/content/13/11/e239241

■ Involvement of the nervous system in COVID-19: the bell should toll in the brain

Sairaj Satarker, Madhavan Nampoothiri

Life Sci. 2020 Dec 1; 262: 118568

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537730/

■ SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation

Kiandokht Keyhanian, Raffaella Pizzolato Umeton, Babak Mohit et al

J Neuroimmunol. 2021 Jan 15; 350: 577436

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647896/

■ COVID-19-associated Guillain-Barre syndrome: atypical para-infectious profile, symptom overlap, and increased risk of severe neurological complications

Mayanja M. Kajumba, Brad J. Kolls, Deborah C. Koltai et al

SN Compr Clin Med. 2020 Nov 21 : 1–13

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680081/

■ Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19-pandemic

Maryam Sharifian-Dorche, Philippe Huot, Michael Osherov et al

J Neurol Sci. 2020 Oct 15; 417: 117085

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413162/

■ Acute Disseminated Encephalomyelitis in COVID-19: presentation of two cases and review of the literature

Lopes, Cesar Castello Branco et al.

Arq. Neuro-Psiquiatr., Dec 2020, vol.78, no.12, p.805-810

https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020001200805&lng=pt&nrm=iso&tlng=en

■ Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital

Studart-neto, Adalberto et al.

Arq. Neuro-Psiquiatr., Aug 2020, vol.78, no.8, p.494-500

https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000800494&lng=pt&nrm=iso

■ The neurology of COVID-19 revised: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries

Gustavo C. Román, Peter S. Spencer, Jacques Reis et al

on behalf of the WFN Environmental Neurology Specialty Group

J Neurol Sci. 2020 Jul 15; 414: 116884

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204734/

■ Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Blog Internet Médica – www.internetmedica.com.br

Data: janeiro 2021

Antibióticos Nefrotóxicos (Nephrotoxic Antibiotics)

Por Paulo Leite 22/01/2021

■ Antibióticos Nefrotóxicos

– aminoglicosídeos

– antivirais

– anfotericina B

– colistina

– polimixina

– sulfadiazina

– quinolonas

– vancomicina

■ Vancomycin nephrotoxicity: vancomycin tubular casts eith characteristic electron microscopic findings

Ngoentra Tantranont, Chizoba Obi, Yosu Luque, Luan D. Truong

Clin Nephrol Case Stud. 2019; 7: 66–72

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921278/

■ Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe gram-positive infections: a practice-based study

José Barberán, José Mensa, Arturo Artero, et al

Rev Esp Quimioter. 2019 Feb; 32(1): 22–30

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372966/

■ The nephrotoxicity of vancomycin

EJ Filippone, WK Kraft, JL Farber

Clin Pharmacol Ther. 2017 Sep; 102(3): 459–46

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579760/

■ Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain throughs between 15 and 2,0 milligrams per liter

J. van Hal, D. L. Paterson, T. P. Lodise

Antimicrob Agents Chemother. 2013 Feb; 57(2): 734–744

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553731/

■ Urinary biomarkers of aminoglycoside-induced nephrotoxicity in cystic fibrosis: kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin

Stephen J. McWilliam, Daniel J. Antoine, Andrea L. Jorgensen et al

Sci Rep. 2018; 8: 5094

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865203/

■ Potentiating aminoglycoside antibiotics to reduce their toxic side effects

Christopher R. Rosenberg, Xin Fang, Kyle R. Allison

PLoS One. 2020; 15(9): e0237948

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467299/

■ Aminoglycoside-induced nephrotoxicity in children

Stephen J McWilliam, Daniel J Antoine, Rosalind L Smyth, Munir Pirmohamed

Pediatr Nephrol. 2017; 32(11): 2015–2025

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624973/

■ A randomized controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis

Stephen J. McWilliam, Anna Rosala-Hallas, Ashley P. Jones et al

Sci Rep. 2020; 10: 1796

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000680/

■ Nephrotoxicity of ciprofloxacin: five cases and a review of the literature

Meriam Hajji, Hela Jebali, Aymen Mrad, et al

Drug Saf Case Rep. 2018 Dec; 5: 17

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906393/

■ Higher dosage of ciprofloxacin necessary in critically III patients: a new dosing algorithm based on renal function and pathogen susceptibility

Emilie M. Gieling, Eveline Wallenburg, Tim Frenzel, et al

Clin Pharmacol Ther. 2020 Oct; 108(4): 770–774

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540326/

■ Escherichia coli resistance to fluoreoquinolones in community-acquired uncomplicated urinary tract infection in women: a systematic review

Ann E. Stapleton, Florian M. E. Wagenlehner et al

Antimicrob Agents Chemother. 2020 Oct; 64(10): e00862-20

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508571/

■ Risk of acute kidney injury associated with the use of fluoroquinolones

Steven T. Bird, Mahyar Etminan, James M. Brophy, et al

CMAJ. 2013 Jul 9; 185(10): E475–E482

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708027/

■ Cefazolin-related acute interstitital nephritis with associated nephrotic-range proteinuria: a case report

Ang Xu, David Hyman, Lee Bach Lu

rug Saf Case Rep. 2018 Dec; 5: 16

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891510/

■ Cefepime induced acute interstitital nephritis – a case report

Kathy Mac, Ruchir Chavada, Sharon Paull, Kenneth Howlin, Jeffrey Wong

BMC Nephrol. 2015; 16: 15

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359532/

■ Molecular mechanisms of colistin-induced nephrotoxicity

Zhibo Gai, Sophia L. Samodelov, Gerd A. Kullak-Ublick, Michele Visentin

Molecules. 2019 Feb; 24(3): 653

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384669/

■ Nephrotoxicity of polymyxins: Is there any difference between colistimethate and polymyxin B?

Alexandre P. Zavascki, Roger L. Nation

■ Colistin-induced nephrotoxicity in a tertiary teaching hospital

D A Al-Abdulkarim, O A Alzuwayed, M Al Ammari et al

Saudi Journal of Kidney Disease and Transplantation ,2020, vol 31 (5): 1057-1061

https://www.sjkdt.org/article.asp?issn=1319-2442;year=2020;volume=31;issue=5;spage=1057;epage=1061;aulast=Al-Abdulkarim